RECURSION PHARMACEUTICALS-ARXRX
ASignal's systematic analysis rates RXRX as Bearish.
Reflects the latest available analysis · analyzed Sep 10, 2026
The case on RXRX
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong cash position with $545.68M in total cash
- Low debt-to-equity ratio of 0.07x indicating minimal leverage risk
- Current ratio of 5.03x suggesting solid short-term financial health
- RSI near neutral zone (42.67), not overbought
- Negative operating margin at -1759.69%
- Negative return on equity (-56.58%) and return on assets (-27.33%)
- Revenue growth YoY at -60.10%
- Negative free cash flow at $-219.49M
- Forward P/E of -3.59x indicating unprofitable earnings trajectory
- EV/EBITDA of -2.63x signaling valuation concerns
See the full verdict on RXRX
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes RXRX
Most investors never get a second opinion, let alone several. ASignal runs RXRX past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.